MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, the cinoany has both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The company derives its products from human placental tissues and process these tissues using its proprietary processing methods, including the PURION® process. The company employs Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce its allografts. MiMedx has supplied over two million allografts, through both direct and consignment shipments.
Company profile
Ticker
MDXG
Exchange
Website
CEO
Timothy R. Wright
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
Alynx, Co.
SEC CIK
Corporate docs
Subsidiaries
MiMedx Tissue Services, LLC • MiMedx Processing Services, LLC ...
IRS number
900300868
MDXG stock data
Analyst ratings and price targets
Current price
Average target
$7.50
Low target
$7.00
High target
$8.00
Mizuho
Initiated
$7.00
HC Wainwright & Co.
Maintains
$8.00
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
30 Nov 22
8-K
Regulation FD Disclosure
17 Nov 22
8-K
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
2 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Departure of Directors or Certain Officers
16 Sep 22
8-K
Departure of Directors or Certain Officers
6 Sep 22
8-K
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Canaccord Genuity 42nd Annual Growth Conference August 2022
10 Aug 22
8-K
MIMEDX Announces Second Quarter 2022 Operating and Financial Results
2 Aug 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
8-K
Regulation FD Disclosure
30 Jun 22
Transcripts
MDXG
Earnings call transcript
2022 Q2
3 Aug 22
MDXG
Earnings call transcript
2022 Q1
4 May 22
MDXG
Earnings call transcript
2021 Q4
1 Mar 22
MDXG
Earnings call transcript
2021 Q3
3 Nov 21
MDXG
Earnings call transcript
2021 Q2
4 Aug 21
MDXG
Earnings call transcript
2021 Q1
29 Apr 21
MDXG
Earnings call transcript
2020 Q4
9 Mar 21
MDXG
Earnings call transcript
2020 Q3
8 Nov 20
MDXG
Earnings call transcript
2020 Q2
11 Aug 20
MDXG
Earnings call transcript
2018 Q1
27 Apr 18
Latest ownership filings
4
Todd Newton
19 Sep 22
4
Robert Benjamin Stein
14 Sep 22
4
Robert Benjamin Stein
16 Aug 22
4
Rohit Kashyap
11 Aug 22
4
Robert Benjamin Stein
8 Aug 22
4
Robert Benjamin Stein
30 Jun 22
SC 13G
Prescience Investment Group LLC
15 Jun 22
4
TIMOTHY R WRIGHT
13 Jun 22
4
Todd Newton
13 Jun 22
4
CATO T LAURENCIN
13 Jun 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 73.22 mm | 73.22 mm | 73.22 mm | 73.22 mm | 73.22 mm | 73.22 mm |
| Cash burn (monthly) | (no burn) | 1.45 mm | 2.79 mm | 2.19 mm | (no burn) | 1.29 mm |
| Cash used (since last report) | n/a | 3.10 mm | 5.97 mm | 4.69 mm | n/a | 2.76 mm |
| Cash remaining | n/a | 70.12 mm | 67.25 mm | 68.53 mm | n/a | 70.45 mm |
| Runway (months of cash) | n/a | 48.4 | 24.1 | 31.3 | n/a | 54.5 |
Institutional ownership, Q3 2022
59.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 139 |
| Opened positions | 12 |
| Closed positions | 22 |
| Increased positions | 44 |
| Reduced positions | 36 |
| 13F shares | Current |
|---|---|
| Total value | 173.15 mm |
| Total shares | 67.94 mm |
| Total puts | 62.20 k |
| Total calls | 24.90 k |
| Total put/call ratio | 2.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Essex Woodlands Management | 23.42 mm | $67.20 mm |
| Prescience Investment | 7.60 mm | $0.00 |
| BLK Blackrock | 7.60 mm | $21.80 mm |
| Vanguard | 6.02 mm | $17.27 mm |
| FHI Federated Hermes | 2.55 mm | $7.31 mm |
| Richmond Brothers | 2.50 mm | $7.18 mm |
| Geode Capital Management | 2.05 mm | $5.90 mm |
| Paradigm Capital Management | 1.14 mm | $3.26 mm |
| Beck Mack & Oliver | 1.03 mm | $2.94 mm |
| NTRS Northern Trust | 1.00 mm | $2.88 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Sep 22 | Newton Todd | Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 325,618 |
| 13 Sep 22 | Robert Benjamin Stein | Common Stock | Sell | Dispose S | No | No | 3.456 | 8,329 | 28.79 k | 278,673 |
| 12 Sep 22 | Robert Benjamin Stein | Common Stock | Sell | Dispose S | No | No | 3.436 | 19,000 | 65.28 k | 287,002 |
| 12 Aug 22 | Robert Benjamin Stein | Common Stock | Sell | Dispose S | No | No | 4.039 | 8,503 | 34.34 k | 306,002 |
| 9 Aug 22 | Rohit Kashyap | Common Stock | Sell | Dispose S | No | No | 4.208 | 12,343 | 51.94 k | 430,072 |
| 4 Aug 22 | Robert Benjamin Stein | Common Stock | Sell | Dispose S | No | No | 3.62 | 19,500 | 70.59 k | 314,505 |
News
MiMedx Group Q3 EPS $(0.09) Misses $(0.08) Estimate, Sales $67.69M Beat $66.73M Estimate
2 Nov 22
Earnings Scheduled For November 2, 2022
2 Nov 22
Stocks That Hit 52-Week Lows On Friday
21 Oct 22
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
13 Oct 22
Mizuho Initiates Coverage On MiMedx Group with Buy Rating, Announces Price Target of $7
13 Oct 22